Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
GLP-1 medications such as Ozempic, Wegovy, and Zepbound support weight loss and blood sugar control, but they can indirectly disrupt hormone balance in perimenopausal Black women. Through rapid fat loss, insulin fluctuations, cortisol shifts, and reduced appetite, these drugs may intensify perimenopause symptoms like hot flashes, mood swings, and irregular menstrual cycles.
Key management strategies include tracking mood, sleep quality, and cycle dates, while prioritizing protein-rich nutrition, strength training, and stress reduction. Because perimenopause and GLP-1 side effects share overlapping symptoms, identifying the root cause is essential for effective care.
Not sure if your symptoms are from perimenopause, your medication, or something else entirely? Guessing wastes time—and the wrong assumption can delay real relief. Take a free, instant, online symptom check to get personalized insights based on your unique health profile. In just a few minutes, you'll better understand what's driving your symptoms and know exactly which next steps to take, whether that's adjusting your routine or talking to your doctor.
Reviewed for medical accuracy: 07/21/2026
Perimenopause—the transitional phase before menopause—brings unpredictable hormone swings, mood shifts and changes in metabolism. Lately, many women are prescribed GLP-1 receptor agonists (like Ozempic, Wegovy and the newly approved Zepbound) to help control weight and blood sugar. If you're a perimenopausal Black woman taking Zepbound or another GLP-1, you may wonder: "Are these meds messing with my hormones—and my mood?" Here's what current research and clinical experience tell us.
Glucagon-like peptide-1 (GLP-1) agonists mimic a hormone that stimulates insulin release, slows stomach emptying and reduces appetite. Common brand names include:
Doctors originally prescribed GLP-1s for type 2 diabetes. Today, many perimenopausal women use them off-label to manage stubborn weight gain—an issue especially common during hormonal transition.
During perimenopause, your ovaries gradually produce less estrogen and progesterone. This fluctuation can lead to:
These shifts affect not only reproductive hormones but also metabolic and stress hormones (cortisol), making perimenopause a uniquely challenging time.
Current evidence suggests GLP-1 medications do not directly reduce estrogen or progesterone. However, they can indirectly affect your hormonal balance in several ways:
Weight Loss and Fat Distribution
Insulin and Cortisol Regulation
Appetite and Nutrition
Menstrual Cycle Changes
Perimenopausal Black women often face higher rates of obesity, hypertension and type 2 diabetes—conditions for which GLP-1s are frequently prescribed. Unique factors include:
These factors can shape how you respond to Zepbound or other GLP-1s, and how you perceive mood swings or menstrual changes. Open communication with your provider is key.
Mood swings are a hallmark of perimenopause. But GLP-1 side effects—nausea, fatigue or low mood—can feel similar. Here's how to spot the difference:
Perimenopause mood swings
GLP-1–related mood effects
Keep a daily log of your mood, appetite, sleep quality and menstrual dates. Over time, patterns emerge—and your doctor can use that data to separate perimenopausal shifts from medication-related effects.
Managing overlapping hormone and medication effects takes a multi-layered approach. Consider:
• Nutrition Focus
• Gentle Movement
• Sleep Hygiene
• Stress Management
• Social Support
Any new or worsening symptom deserves attention—especially if it's life-threatening or severely impacts daily life. Consider seeking medical advice if you experience:
If you're experiencing concerning symptoms but aren't sure whether they warrant an immediate doctor visit, you can use Ubie's Medically approved LLM Symptom Checker Chat Bot to help you understand your symptoms and decide on the best next steps before your appointment.
Regular follow-ups help your provider fine-tune therapy. You may discuss:
Always report new or troubling symptoms honestly—your safety and quality of life depend on it.
Always speak with a healthcare provider about any persistent, severe or worrisome symptoms. Your well-being is too important to leave to guesswork—professional guidance ensures you get the safest, most effective care.
(References)
* Khedr, E., Awad, O., El-Bahy, M. R., & Sabry, A. (2022). Glucagon-like peptide-1 (GLP-1) and sex hormones: A narrative review. *Journal of Clinical Endocrinology & Metabolism*, *107*(10), e4133-e4141.
* He, M., Zhao, S., Sun, J., & Ma, R. (2023). Impact of GLP-1 Receptor Agonists on Endocrine Systems: A Comprehensive Review. *Journal of Clinical Endocrinology & Metabolism*, *108*(10), 2530-2544.
* Harsløf, T., & Jensen, T. A. (2021). Metabolic and hormonal effects of GLP-1 receptor agonists beyond glucose lowering in type 2 diabetes. *Endocrinology, Diabetes & Metabolism*, *4*(4), e00270.
* Aiyer, A., Williams, N., Aravind, A. J., & Gadgil, K. K. (2024). Racial and ethnic disparities in response to weight loss medications in adults with overweight or obesity: a systematic review. *Obesity Reviews*, *25*(3), e13645.
* Sun, S., Wang, F., Guo, F., Li, Z., & Gao, R. (2024). The role of GLP-1 in female reproductive health: a systematic review. *Frontiers in Endocrinology*, *15*, 1342676.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.